It has also been shown that the activation of SLAM by an mAb agonist in Th2 cells derived from the skin of patients with atopic dermatitis results in stable populations of IFN-gamma-producing cells that do not support IgE synthesis, potentially attenuating the allergic process. Here, IFNG is linked to atopic eczema.